Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review article found no concrete evidence supporting the existence of "silicone implant illness" as a new syndrome, despite the association of various symptoms with breast implants which are considered safe according to current evidence.

This review summarizes existing knowledge on androgen receptor activity in breast cancer and reports no new clinical findings, with emphasis on therapies targeting androgen signaling in specific BC subtypes.

This study found that AR/VDR-targeted agonist hormone therapy can inhibit cell viability in HR2-av triple-negative breast cancer cell lines through multiple mechanisms and may enhance the effects of chemotherapy.

This study observed that in hormone-starved prostate cancer cells, the androgen 5alpha-dihydrotestosterone rapidly induces matriptase activation and shedding, which involves androgen receptor signaling and requires both transcription and protein synthesis.

This study found that female breast cancer survivors using aromatase inhibitors were observed to have a higher likelihood of experiencing hair loss and thinning compared to those not treated with these drugs.

This study identified a specific SNP in the CACNB4 gene associated with a higher risk of chemotherapy-induced alopecia in breast cancer patients, which may help develop interventions to improve their quality of life.

This case report describes a woman with Becker's nevus and ipsilateral breast hypoplasia who showed breast enlargement after one month of spironolactone treatment, suggesting a link between hypoplasia and increased androgenic receptor activity.

This study validated the Black Identity, Hair Product Use, and Breast Cancer Scale (BHBS) as a tool to measure social and cultural factors related to hair product use and perceived breast cancer risk in Black women.

This study found that chemotherapy in female breast cancer patients caused significant early hair loss, which began to recover three months after completion, whereas tamoxifen did not affect hair growth.

In this review, researchers found no evidence of interactions between 5α-reductase inhibitors or spironolactone and endocrine therapies for breast cancer, with no consistent changes in estrogen levels or increased breast cancer risk associated with spironolactone usage.

Breast pain is common and usually not linked to cancer, with treatment varying by severity.

This study found that adjuvant docetaxel treatment for breast cancer at cumulative doses of 400 mg/m² or higher is associated with a 10% prevalence of persistent alopecia leading to wig use, but this was completely prevented with scalp cooling.

This review discusses the potential link between long-term transdermal exposure to sex hormones from antiperspirants and increased breast and prostate cancer rates, calling for further research to confirm this theory.

A specific hair diffraction pattern may indicate breast cancer if tested with the correct method.

This case report describes a patient with breast cancer who developed female androgenetic alopecia after starting tamoxifen therapy.

This study indicates that ABCG2 expression identifies interfollicular keratinocyte progenitor cells in human epidermis and suggests it could help enrich these stem cells for research and treatment.

This study reported that subcutaneous trastuzumab improved certain symptoms and did not negatively impact health-related quality of life in patients with early or metastatic HER2-overexpressing breast cancer.

This study found that the combination of mammography and hair X-ray diffraction increased sensitivity for detecting breast cancer compared to using each method alone.

This review characterizes breast implant illness and its autoimmune symptoms, reporting an association between breast implants and autoimmune diseases, with explantation relieving symptoms in over half of patients.

This study found that quality of life, overall survival, and progression-free survival are the most important factors for postmenopausal patients with advanced breast cancer when considering treatment options.

This study found that spironolactone was not independently associated with increased breast cancer recurrence and may be considered for treating alopecia in survivors.

This study found that in estrogen receptor-positive breast cancer cells, 17β-estradiol repressed polyamine oxidase transcription by interacting with AP-1 sites on its promoter.

This study highlights significant unmet medical needs among breast cancer patients due to inadequate solutions for managing treatment-related adverse events and reveals varied information needs regarding these events.

This study suggests that breast cancer-associated phospholipids may alter the X-ray diffraction pattern of hair, potentially enabling the development of a sensitive and specific screening test for breast cancer.

This literature review underscores the need for healthcare professionals to address both the psychological and physical effects of breast cancer to improve patient quality of life.

This article highlights the need for oncologists to better understand the profound impact of chemotherapy-induced alopecia on Black breast cancer patients, recognizing its unique historical and cultural significance.

This study aims to evaluate the effectiveness of YH0618 granules in preventing chemotherapy-induced hair loss in breast cancer patients through a randomized, double-blind, multi-center clinical trial, focusing on potential mechanisms related to kidney deficiency as understood in Chinese Medicine. Results are not yet reported.

This study found that applying a 1% sodium N-(dihydrolipoyl)-l-histidinate zinc complex lotion to the scalp did not prevent chemotherapy-induced alopecia in breast cancer patients, but it may aid recovery.

This review highlights the importance of recognizing neoplastic alopecia as a potential indicator of underlying metastatic neoplasia, as it may be mistaken for other scalp conditions like alopecia areata.

The lotion CG428 did not show effectiveness in treating permanent hair loss in breast cancer survivors.